Authors
Latest:
Test and Learn: Making Confident Decisions on the Commercial SideCompanies that adopt this new methodology will have a longstanding competitive advantage over those companies conducting business as usual.
Latest:
The Growing Pediatrics MarketPediatric drugs require investments in formulation, but the market opportunity is worth the cost.
Latest:
Embedding Market Access in Today's Pharma Business ModelA proactive approach to talent and organization planning is the hidden trump card in prevailing with payers.
Latest:
Embedding Market Access in Today's Pharma Business ModelA proactive approach to talent and organization planning is the hidden trump card in prevailing with payers.
Latest:
Remember the doctor's nameThere's no better way to attract a doctor's attention than to mention his or her name.
Latest:
High Price of Gilead's Sovaldi Could Deter Early Hep C TreatmentGilead Silences has cleaned up on their new $1,000 Hepatitis C pill Sovaldi (84,000 per treatment), hauling in a record-breaking $2.3 billion in its first full quarter on the market.
Latest:
CRM Checklist for SuccessCustomer relationship management (CRM) has become a pharma buzzword, but few companies actually practice it. That is about to change.
Latest:
Safe and SecureElectronic product codes (EPCs) provide a nearly perfect solution for many of pharma's problems with counterfeiting, diversion, theft, and the like.
Latest:
European Pharma Depressed by German PricingGermany has shifted from relative pricing freedom to a market that is sensitive and influenced by cost-containment policies. But pharma is pressuring the country to change its policy again.
Latest:
After the Mad DashNow that the pharma sales rep market has reached its saturation point, companies must focus on retention.
Latest:
How to Choose a Medical AnimatorFor a rendering to be effective, the right balance must be struck between captivating art and accurate science.
Latest:
How to Choose a Medical AnimatorFor a rendering to be effective, the right balance must be struck between captivating art and accurate science.
Latest:
The Push for Modern ManufacturingAntiquated manufacturing processes cost pharma money-a fact widely known and accepted in the industry. At some facilities, rejected batches, rework, and lengthy investigations have become a way of life, and by some estimates can inflate production costs by as much as 10 percent. According to G.K. Raju, executive director of the Pharmaceutical Manufacturing Initiative at the Massachusetts Institute of Technology, manufacturing consumes an estimated 25 percent of drug company revenues.
Latest:
How reps sell around the globe'Snapshots' of selling environments from other parts of the world.
Latest:
Safe and SecureElectronic product codes (EPCs) provide a nearly perfect solution for many of pharma's problems with counterfeiting, diversion, theft, and the like.
Latest:
Test your techno-vocabularyHow familiar are you with today's technological terms? See if you can match the terms listed on the left with their definitions on the right. (Answers appear at bottom of page.)
Latest:
Super-Size Me: Optimizing the Information ExplosionOptions for using data have proliferated to the point of becoming overwhelming. So what opportunities does this information explosion present?
Latest:
HCP Giveaways: Get RealThe Patient Protection and Affordable Care Act (?PPACA?) requires manufacturers to record, aggregate and report to the federal government ?payments and other transfers of value? to a covered recipient. This article will focus on the two key convention-related items under PPACA: food and educational products.
Latest:
Minimizing the Risk of Mistakes in HTAWe all make mistakes — and that includes those involved in Health Technology Assessment (HTA). Following an error made by ICER this year, Leela Barham looks at similar mistakes made in the past and what can be done about them.
Latest:
HCP Giveaways: Get RealThe Patient Protection and Affordable Care Act (?PPACA?) requires manufacturers to record, aggregate and report to the federal government ?payments and other transfers of value? to a covered recipient. This article will focus on the two key convention-related items under PPACA: food and educational products.
Latest:
The New Metrics of Market SuccessProfitability now depends on metrics to help companies answer a key strategic question: "stay the course" with more investment in sales and marketing? Or "stand down" and deploy those scarce assets somewhere else?
Latest:
Time to Appoint a 'Chief Patient Officer'?Sarah Krug asks if it is time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust.
Latest:
Recommendations for Accelerating Cell and Gene TherapiesWhile there are many successes to show for its decades of development, there remain four substantial problems that impede the velocity with which cell and gene therapies can be brought to market. Despite the intricacies of these issues, there are emerging solutions to address them. If the biopharma industry can develop these solutions on a broad scale, cell and gene technologies can accelerate and fulfill the early promise of regenerative medicine.
